Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom Search results
44 results
- Ulcerative colitisUlcerative colitis Homepage Indications Ulcerative colitis Ulcerative colitis Ulcerative colitis is one of the disorders known as inflammatory bowel disease (IBD). Other disorders within this group of…
- Crohn’s DiseaseCrohn’s Disease Homepage Indications Crohn’s Disease Crohn’s Disease Crohn’s disease belongs to the group of disorders known as inflammatory bowel disease. Definition A diagnosis of “Crohn’s disease”…
- Primary Biliary CholangitisPrimary Biliary Cholangitis Homepage Indications Primary Biliary Cholangitis Primary Biliary Cholangitis Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the small bile ducts in…
- Eosinophilic OesophagitisEosinophilic Oesophagitis Homepage Indications Eosinophilic Oesophagitis Eosinophilic Oesophagitis Eosinophilic oesophagitis (abbreviated EoE) is a condition characterised by chronic inflammation of…
- Dr. Falk Pharma AustraliaINNOVATION DRIVES EVERYTHING Dr. Falk Pharma in Australia – the experts in digestive and metabolic medicine Learn more Innovation drives everything we do Dr. Falk Pharma – Innovation drives everything…
- Contact usContact us Homepage Contact us Thank you for your interest in our company. If you have any questions or suggestions please do not hesitate to contact us. We will be happy to connect you with the…
- NEWSROOMRenexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-nonresponsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed TerritoriesROSCREA, Ireland, and FREIBURG, Germany (GLOBE NEWSWIRE) [February, 7, 2024]– Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to…